

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 6855)

Voluntary Announcement

APG-2575 completed dosing of first patient in Phase Ib/II trial in the U.S.

Ascentage Pharma Group International (the “**Company**”) is pleased to announce that Phase Ib/II trial of APG-2575, a novel Bcl-2 selective inhibitor as a single agent or in combination with rituximab/acalabrutinib for the treatment of relapsed/refractory chronic lymphocytic leukemia (r/r CLL) or small lymphocytic lymphoma (r/r SLL) has recently completed dosing of its first patient in the U.S.

This global multicenter, open-label Phase Ib/II dose-escalation and dose-expansion study is designed to evaluate the safety, tolerability, and anticancer activity of APG-2575 as a single agent or in combination with rituximab or acalabrutinib in patients with r/r CLL/SLL.

APG-2575 is a novel, orally administered Bcl-2 selective inhibitor being developed by the Company. The Phase I trial of APG-2575 in hematological malignancies is ongoing in the U.S. and Australia. APG-2575 is also the first China-made Bcl-2 selective inhibitor to enter clinical trials in China. APG-2575 has just received three approvals in the U.S and China for Phase Ib/II clinical trials including the trial mentioned above. The Company will actively carry forward the product’s clinical studies globally, in hope of providing benefits for the patients soon.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: We cannot guarantee that we will be able to obtain further approval for, or ultimately market, APG-2575 successfully.

By order of the Board
Ascentage Pharma Group International
Dr. Yang Dajun
Chairman and Executive Director

Suzhou, People's Republic of China, March 23, 2020

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng, Dr. Tian Yuan, Mr. Zhao Qun, Dr. Lu Simon Dazhong and Mr. Liu Qian as non-executive Directors, and Mr. Ye Changqing, Dr. Yin Zheng and Mr. Ren Wei as independent non-executive Directors.